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ABSTRACT Adrenomedullin (AM) is a pluripotent regulatory peptide initially isolated from a
human pheochromocytoma (adrenal tumor) and subsequently shown to play a critical role in cancer
cell division, tumor neovascularization, and circumvention of programmed cell death, thus it is an
important tumor cell survival factor underlying human carcinogenesis. A variety of neural and
epithelial cancers have been shown to produce abundant amounts of AM. Recent findings have
implicated elevation of serum AM with the onset of malignant expression. In addition, patients with
tumors producing high levels of this peptide have a poor prognostic clinical outcome. Given that
most human epithelial cancers display a microenvironment of reduced oxygen tension, it is inter-
esting to note that AM and several of its receptors are upregulated during hypoxic insult. The
existence of such a regulatory pathway has been implicated as the basis for the overexpression of
AM/AM-R in human malignancies, thereby generating a subsequent autocrine/paracrine growth
advantage for the tumor cell. Furthermore, AM has been implicated as a potential immune
suppressor substance, inhibiting macrophage function and acting as a newly identified negative
regulator of the complement cascade, protective properties which may help cancer cells to circum-
vent immune surveillance. Hence, AM’s traditional participation in normal physiology (cited
elsewhere in this issue) can be extended to a primary player in human carcinogenesis and may have
clinical relevance as a biological target for the intervention of tumor progression. Microsc. Res.
Tech. 57:110–119, 2002. Published 2002 Wiley-Liss, Inc.†
INTRODUCTION
Adrenomedullin (AM) was originally identified in
1993 as a peptide isolated from a human endocrine
tumor (pheochromocytoma), shown to stimulate adeny-
lyl cyclase and to function as a vasodilator in vivo
(Kitamura et al., 1993). This initial finding was rapidly
followed by a series of discoveries which demonstrated
AM to be a ubiquitous peptide found in a variety of
tissues and operating as a crucial modulator of diverse
physiological activities (Martı´nez and Cuttitta, 1998).
AM is found in literally all organs of the body, from
classic endocrine tissues (pituitary, adrenals, thyroid,
pancreas, ovary, and testis), to anatomically distinct
regions (brain, heart, lung, kidney, bladder, liver, thy-
mus, spleen, and GI tract), to areas of the body giving
support, movement, sensory, or protective capabilities
(bone, cartilage, muscle, hair, and skin) (Martı´nez and
Cuttitta, 1998). This peptide and immunologically re-
lated molecules have been found throughout the ani-
mal kingdom, represented in vertebrate (mammals,
birds, reptiles, amphibians, and fish) and nonverte-
brate (echinoderms) species (Lo´pez et al., 1999; Mar-
tı´nez et al., 1996a). Based on this evolutionary conser-
vation, extending over millions of years of animal ad-
aptation, it is thought that AM plays a fundamental
role in some aspect of species survival (Martı´nez and
Cuttitta, 1998; Cuttitta et al., 1999). Supporting such
thinking, AM has been demonstrated to be a pluripo-
tent peptide modulating cardiovascular tone (Nuki et
al., 1993; Ishiyama et al., 1993; Parkes, 1995), central
brain activity (Murphy and Samson, 1995; Martı´nez et
al., 1997a), bronchoelasticity (Kanazawa et al., 1994),
hormone release (Samson et al., 1995; Martı´nez et al.,
1996b), renal output (Ebara et al., 1994), apoptosis
(Kato et al., 1997), angiogenesis (Zhao et al., 1998), cell
growth (Cuttitta et al., 1999), and immune response
(Kamoi et al., 1995; Kubo et al., 1998a; Allaker et al.,
1999). These latter four functions are key components
underlying the related growth processes of embryogen-
esis, wound repair, and carcinogenesis.
Rapid cell growth is a universal characteristic of fetal
development, wound healing, and tumor progression.
Over the past two decades of scientific study, it has
become increasingly clear that factors which regulate
growth in the normal setting are the same factors
which modulate malignant cell proliferation (Naka-
mura and Matsumoto, 1994). In the normal configura-
tion there are appropriate check-and-balance points
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which allow for precise spatiotemporal control of cell
growth, while in cancer regulation of growth cessation
is corrupted (Hanahan and Weinberg, 2000). In the
following we summarize our current understanding of
AM’s role in human carcinogenesis (promotion/inva-
sion/metastasis) and demonstrate its potential use as a
clinical target for the intervention of malignant dis-
ease.
AM EXPRESSION IN HUMAN
TUMOR TISSUE
As previously stated, AM was first identified as a
peptide product of a human adrenal tumor (pheochro-
mocytoma) and has later been localized in a variety of
neural and epithelial cancers. Satoh et al. (1995) re-
ported that AM was not only expressed in different
regions of the brain but also found in neural tumors
such as ganglioneuroblastoma and neuroblastoma. In a
related observation, Zimmermann et al. (1995) re-
ported that a human neuroblastoma cell line, SK-
N-MC, could bind AM through what appeared to be the
calcitonin gene-related peptide (CGRP) receptor and
stimulate cAMP production. This was the first indica-
tion that a possible autocrine/paracrine mode of action
could take place within tumor cells producing AM. The
next anatomical cancer site to be established as a pro-
ducer of AM was the lung. Using immunohistochemical
and molecular techniques, Martı´nez et al. (1995) were
able to demonstrate abundant expression of AM in
airway epithelium and in cancer cell lines or tumors
derived from this region (small cell carcinoma, adeno-
carcinoma, bronchioalveolar carcinoma, and carci-
noids). As a further extension to this study, these same
investigators found that a variety of human epithelial
cancer cells derived from the lung, colon, breast, ovary,
prostate, cartilage, and bone marrow could produce AM
and express one of the putative AM receptors (AM-R)
(Miller et al., 1996). In addition, they showed that AM
could function as an autocrine growth factor for certain
cancer cell lines and that a neutralizing monoclonal
antibody to this ligand, MoAb-G6, could block this ac-
tivity (Miller et al., 1996). Furthermore, it was noted
that AM induced a cAMP response in cancer cell lines
(Miller et al., 1996). Interestingly, a previous report by
Withers et al. (1996) had demonstrated AM to be mi-
togenic for Swiss 3T3 mouse fibroblast cells via a
cAMP-dependent pathway. These collective findings
therefore implicated the AM/AM-R interactive auto-
crine system as a potential mechanism driving tumor
proliferation in vivo.
Several subsequent articles have confirmed AM’s
proliferative function in cancer cells having diverse
anatomical origins. The human melanoma cell line
CRL-7585 was determined to express AM message/
protein and selectively bind 125I-labeled AM, which
could not be inhibited with PAMP, AM22-52, CGRP,
CGRP8-37, or amylin, thereby demonstrating ligand
specificity (Martı´nez et al., 1997b). In addition, exoge-
nous AM induced a dose-dependent stimulation of 3H-
thymidine uptake by this skin cancer cell (Martı´nez et
al., 1997b). Similarly, studies by Kapas et al. (1997)
showed that exogenous AM could activate adenylyl cy-
clase in the oral squamous cell line H357, a signal
transduction event which stimulated the growth of this
cancer cell. This peptide-induced proliferative activity
could be blocked by the adenylyl cyclase inhibitor,
SQ22-536 or mimicked by the exogenous addition of the
cell permeable cAMP analog dibutyryl cAMP (Kapas et
al., 1997). In addition, those investigators found that
the AM-mediated mitogenic response in H357 was not
suppressed by inhibitors of the PKC or tyrosine kinase
pathways, nor by the CGRP receptor antagonist
CGRP8-37, demonstrating ligand and internal signaling
specificity.
Research on glial cell tumors of the brain by Taka-
hashi et al. (1997) from the Tohoku University School
of Medicine, working with cell lines and pathological
specimens, clearly demonstrate a potential autocrine
involvement of AM in these cancers. AM mRNA and
protein were found in the glioblastoma cell lines T98G
and A172, while immunoreactive HPLC resolvable el-
ements were detected in tissue from astrocytomas and
glioblastomas (Takahashi et al., 1997). Interferon
gamma (INF) and interleukin 1 beta (IL-1) treat-
ment of T98G cells caused a dose-dependent increase in
transcriptional/translational AM products, while tu-
mor necrosis factor alpha (TNF) inhibited their ex-
pression (Takahashi et al., 1997). In addition, this
group found that nanomolar concentrations of exoge-
nous AM would augment adenylyl cyclase activity in
T98G, implicating the possibility for an autocrine reg-
ulatory mechanism to exist in glioblastoma cells. In
related experiments with the C6 rat glioma cell line,
Moody et al. (1997) demonstrated that this tumor cell
bound 125I-AM with high affinity (Kd  24 nM) and
they determined by Scatchard analysis that the ligand
binding takes place through a single class of sites with
approximately 36,000 receptors per cell. Exogenous ad-
dition of AM to this rat glioma cell line caused a dose-
dependent increase in intracellular cAMP and a com-
parable increase in c-fos mRNA expression (Moody et
al., 1997).
Interestingly, during the past several years a variety
of clinical studies have begun to demonstrate an inti-
mate involvement of AM with malignant disease. Ini-
tial testing by Ehlenz et al. (1997) showed elevated AM
levels in the plasma of patients with lung and gastro-
intestinal cancers. Intraocular and orbital human tu-
mors have been shown to have significantly higher AM
mRNA expression (P  0.05 to P  0.005) than similar
anatomical tissue from nonmalignant disorders, in-
cluding proliferative vitreoretinopathy, proliferative
diabetic retinopathy, preretinal macular fibrosis, and
acute retinal necrosis (Udono et al., 2000). Patients
with Cushing’s syndrome due to pituitary adenoma
had markedly higher circulating AM levels than did
normal controls and, following surgical excision of the
tumor, AM concentrations dramatically decreased
(Letizia et al., 2000). AM has been recently identified in
leiomyomas, a common benign tumor of the uterus, and
has been suggested to play an important role in stim-
ulating neovascularization around the tumor body
(Hague et al., 2000). Clinical observations by Hata et
al. (2000), evaluating 60 cases of epithelial ovarian
cancer, revealed that the level of AM gene expression
detected in the tumor is significantly associated with
histological grade and poor prognosis. In 20 cases of
prostate cancer, a marked increase in AM mRNA ex-
pression was noted in tissue samples from patients
having high Gleason’s scores (Rocchi et al., 2000). From
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this cumulative clinical data it becomes increasingly
clear that elevated AM expression is associated with a
variety of human tumors and this ligand could poten-
tially be used as a marker or intervention target of
malignant disease. Table 1 is a summary of the ana-
tomical types of cancer cells associated with AM/AM-R
expression and the growth effect mediated by ligand/
receptor interaction.
AM RECEPTORS AND SIGNAL
TRANSDUCTION PATHWAYS
Several receptors and a variety of signal transduc-
tion pathways have been associated with AM bioac-
tivity (see accompanying articles of this issue). All of
the receptors thus far identified have been members
of a seven-transmembrane G-protein associated su-
perfamily. Two of these receptors were identified/
characterized by the same investigative group, one
denoted as L1, which had an exclusive binding rec-
ognition capability for AM, and the other RDC1,
which selectively bound CGRP over AM (Kapas et al.,
1995; Kapas and Clark, 1995). A third receptor sys-
tem has been recently identified which represents a
heterodimeric complex of the previously recognized
moiety, calcitonin-receptor-like receptor (CRLR) and
a newly established partner, receptor-activity-modi-
fying proteins (RAMPs) (McLatchie et al., 1998). It
has been determined that there are several RAMP
molecules which specify ligand recognition and have
the following binding pattern; CRLR  RAMP1 is
selective for CGRP, while CRLR  RAMP2 or
RAMP3 have selective recognition for AM. Ligand
binding to L1, RDC1, or CRLR/RAMP complex medi-
ates an elevated response in intracellular cAMP. The
major intracellular signaling mechanism of AM ap-
pears to be cAMP, although Ca2 mobilization, ino-
sitol 1,4,5-trisphosphate, protein kinase A (PKA),
mitogen-activated protein kinase (MAPK), Max,
phosphatidylinositol 3-kinase/Akt (PI3K/Akt), and
cGMP have also been implicated (Kitamura et al.,
1993; Withers et al., 1996; Kapas et al., 1997;
Shimekake et al., 1995; Uezono et al., 1998; Shichiri
et al., 1999; Semplicini et al., 2002; Nishimatsu et
al., 2001). Given the respective receptor pedigrees
and signal transduction pathways associated with
AM biology, one could envision a multitude of inter-
vention strategies targeted to disrupt ligand/recep-
tor which could potentially have clinical applications
in the treatment of cancer.
INFLAMMATION AND HYPOXIA
UPREGULATE AM EXPRESSION IN CANCER
CELLS, DRIVING TUMOR GROWTH AND
POTENTIALLY SUBVERTING IMMUNE
SURVEILLANCE MECHANISMS
Two major pathways recently recognized for their
contributions to human carcinogenesis are the cellular
processes of inflammation and hypoxic insult (Hana-
han and Weinberg, 2000; Coussens and Werb, 2001;
Balkwill and Mantovani, 2001; Brown and Giaccia,
1998; Zhong et al., 1999). Chronic inflammation has
been shown to be one of the leading mechanisms un-
derlying malignant transformation (Balkwill and Man-
tovani, 2001). Silica, asbestos, and cigarette smoking
are major contributors to the onset of lung cancer,
while papillomavirus and Helicobacter pylori infections
increase the risk of cervical or gastric cancers, respec-
tively (Balkwill and Mantovani, 2001). Leukocytic in-
filtrates in and around the tumor body have now been
shown to release a variety of bioactive proteins (i.e.,
basic fibroblast growth factor [b-FGF], vascular endo-
thelial growth factor [VEGF], monocyte chemotactic
protein-1 [MCP-1], and matrix metalloproteinase-9
[MMP-9]) which can augment cancer cell growth and
metastasis (Hanahan and Weinberg, 2000; Coussens
and Werb, 2001). Similarly, low oxygen tension is
known to upregulate the expression of several genes
(i.e., transferrin, endothelin-1, and VEGF) important
in maintaining cell viability during hypoxic insult
(Wenger and Gassmann, 1997). Since most solid tu-
mors have areas of regional hypoxia, the above-men-
tioned growth factors are enriched around the tumor
body and thereby augment cancer cell growth (Brown
and Giaccia, 1998; Zhong et al., 1999). In the following
sections we discuss the role of AM in inflammation and
hypoxia and how this relationship may contribute to
human carcinogenesis.
TABLE 1. AM/AM-R Expression in cancer cells and biological effect
Pathology Ligand Receptor Action Reference
Lung cancer
Small cell CA   n.d. Martinez et al., 1995; Miller et al., 1996
Adeno CA   n.d. Martinez et al., 1995; Miller et al., 1996
Large cell CA   n.d. Martinez et al., 1995; Miller et al., 1996
Bronchioloalveolar CA   n.d. Martinez et al., 1995; Miller et al., 1996
Squamous CA   Growth1 Martinez et al., 1995; Miller et al., 1996
Carcinoid   Growth1 Martinez et al., 1995; Miller et al., 1996
Colon cancer   n.d. Nakayama et al., 1998; Miller et al., 1996
Breast cancer   cAMP1/Growth1 Miller et al., 1996
Ovarian cancer   Growth1 Miller et al., 1996; Hata et al., 2000
Prostate cancer   Growth1 Miller et al., 1996; Rocchi et al., 2001
Brain cancer
Glioblastoma   n.d. Satoh et al., 1995
Neuroblastoma   cAMP1/Growth2 Cuttitta et al., 1999; Satoh et al., 1995
Skin cancer
Melanoma   Growth1 Martı´nez et al., 1997
Oral squamous CA   cAMP1/Growth1 Kapas et al., 1997
Carcinoma, CA; 1stimulation; 2suppression; n.d., not done.
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AM and Inflammation
There have been several reports in the scientific lit-
erature which implicate AM in inflammation. Initial
studies by Sugo et al. (1994, 1995) showed that lipo-
polysaccharide (LPS) and the cytokines it induced to be
released from activated lymphocytes/macrophages
(IL-1 and TNF) stimulated AM production in rat vas-
cular smooth muscle cells. A similar LPS/IL-1/TNF
induced AM producing relationship has been demon-
strated for rat endothelial cells (Isumi et al., 1998). In
the rat model, intravenous injection of bacterial endo-
toxin resulted in augmentation of AM plasma levels
and increased AM mRNA expression in the liver, heart,
aorta, ileum, and kidney (Shoji et al., 1995). Along
these same lines, clinical assessment of septic shock
patients showed AM plasma concentrations which
were 10–15 times higher than normal controls and AM
urine levels that were elevated in children with urinary
tract infections (Hirata et al., 1996; Dotsch et al., 1998).
Given the accumulated evidence regarding AM re-
sponses to bacterial endotoxin in laboratory animals
and humans, it becomes evident that this peptide may
encompass some type of host protection against micro-
bial pathogens. AM has recently been shown to have an
antimicrobial-like ability, causing the lysis of bacterial
and fungal organisms via membrane pore formation
similar to other peptide defensins (Allaker et al., 1999,
Zasloff, 1987; Walsh et al., 1996).
The ability of macrophages to produce AM in re-
sponse to LPS, TNF, INF-, taxol, retinoic acid, and
phorbol esters has been studied extensively (Kubo et
al., 1998a, 1998b; Zaks-Zilberman et al., 1998). Using a
murine macrophage cell line (RAW 246.7) immortal-
ized with Abelson leukemia virus, Kubo et al. (1998a)
have shown that AM could increase the basal secretion
of TNF- in this target cell, thus acting as an immune
enhancer in this setting. Conversely, however, these
same investigators have demonstrated that AM can
suppress LPS-induced TNF- and interleukin-6 secre-
tion from RAW 246.7 cells. Such seminal studies imply
that AM can act as an autocrine/paracrine regulator of
the immune response mechanism. Thus, depending on
the microcellular environment in which AM is intro-
duced, it can function to augment or blunt the immune
response capacity of macrophages. Experimental anal-
ysis of rat alveolar macrophages revealed the ability of
AM to stimulate intracellular cAMP and block cyto-
kine-induced neutrophil chemoattractant (CINC) re-
lease in a dose-dependent fashion, again confirming the
suppressive effect that AM can have on macrophage
function (Kamoi et al., 1995).
We have recently established human complement
factor H (fH) as a serum binding protein for AM and
that purified fH augments the ability of AM to induce
cAMP response in Rat-2 fibroblast cells (Pı´o et al.,
2001; for a review of this subject, see accompanying
article in this issue). Complement fH is one of the key
serum proteins responsible for the downregulation of
complement mediated lysis (Pangburn and Mu¨ller-
Eberhard, 1983). It binds C3b, complexes with factor I
(a proteinase), and rapidly degrades this key comple-
ment cascade protein, hence blocking complement lysis
(Pangburn and Mu¨ller-Eberhard, 1983). We have
shown that AM can cause a dose-dependent increase in
the ability of the fH/fI complex to proteolytically cleave
C3b (Pı´o et al., 2001). Recent studies with the human
H2 glioblastoma cell line have shown that cancer cells
can produce fH, and in so doing become extremely
resistant to complement mediated lysis (Junnikkala et
al., 2000; Fedarko et al., 2000). Hence, human tumor
cells producing both fH and AM would potentially have
a selective capacity to circumvent immune surveillance
via enhanced suppression of the complement cascade
pathway.
Based on the previously outlined involvement of AM
in inflammation that includes the ability of endotoxins/
cytokines to augment AM mRNA expression, the ca-
pacity of AM to suppress cytokine release from acti-
vated leukocytic target cells and the potential inhibi-
tory role AM plays in complement lysis, an
overwhelming amount of information has been com-
piled which suggests that AM may function as a tumor
protection factor assisting cancer cells to evade im-
mune surveillance mechanisms.
Hypoxia Upregulates AM/AM-R Expression
Initial studies by the Hammersmith group in the UK
demonstrated that environmental exposure to 7-day
chronic hypoxia in experimental rats did not augment
AM mRNA or protein expression in the lung (Zhao et
al., 1996). Unfortunately, no serum level data was
available from this study. Interestingly, this group re-
ported that the upper airway binding of 125I-AM and
125I-CGRP dramatically increased over the 7-day pe-
riod of reduced oxygen tension, indicating the possibil-
ity of hypoxia-mediated AM/CGRP receptor upregula-
tion. This preliminary finding was eventually con-
firmed by other laboratories 5 years later (Ladoux and
Frelin, 2000; Qing et al., 2001). The first report in the
literature which actually linked hypoxia to AM expres-
sion was that of Wang et al. (1995), who demonstrated
dramatic increases in AM mRNA levels (17.4-fold to
21.7-fold enhancement of message) when studying
ischemic insult in the brain of experimental rats using
differential display analysis. These investigators also
found augmented immunohistochemical staining for
AM at the site of the ischemic lesion, implying that
hypoxic stress could upregulate both transcriptional
and translational products of this gene. Subsequent
studies on patients and animals with heart failure
showed similar results, revealing enhanced AM plasma
concentrations mediated by diminished cardiovascular
oxygen tension (Kato et al., 1996; Nishikimi et al.,
1997; Jougashaki et al., 1997). Similarly, Cheung and
Leung (1997) described elevated plasma levels of the
peptide in patients with chronic obstructive pulmonary
disease (COPD) with hypoxia. These investigators sug-
gested the observed increased levels of plasma AM in
COPD patients were due to a compensatory response
by the host to enhance blood flow via peptide-induced
vasodilation. Another early study implicating hypoxia
as an upregulator of AM expression was performed on
high-altitude mountaineers (Toepfer et al., 1998). Male
and female volunteers were evaluated as to their re-
spective AM plasma levels following high-altitude as-
cent by comparing values measured at 1,782 ft (basal)
to that observed at 15,048 ft (test), which showed clear
statistical differences between the two figures. One
major concern about this study is that no consideration
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was given to the role of exercise-induced AM expres-
sion when screening the mountaineers for their pre-
sumptive hypoxia-mediated change in blood peptide
levels. Strenuous exercise had been previously shown
to augment AM plasma concentrations (Tanaka et al.,
1995; Piquard et al., 2000) and in the mountaineer
study, subjects underwent a 5-hour climb to achieve
their endpoint test altitude, thus potentially tainting
the data. It was not until several years later that re-
searchers began to establish a relationship between
hypoxia, AM, and carcinogenesis.
A study by Nakayama et al. (1998) was the first
report to clearly demonstrate the modulatory relation-
ship hypoxia had on AM expression in human tumor
cells. These investigators exposed human colorectal
carcinoma cells (DLD-1) to low oxygen tension, which
in turn caused a rapid time-dependent increase in AM
message expression, accompanied by a similar increase
of detectable immunoreactive peptide in the condi-
tioned medium. In addition, they showed that the
heavy metal CoCl2, a hypoxia mimetic, also caused a
parallel time-dependent increase in AM mRNA/protein
levels. HPLC purification techniques were used to val-
idate the authenticity of the immunoreactive peptide
found in the conditioned media as native AM. Finding
no hypoxia response elements (HRE) in the 5 up-
stream flanking region of the human AM gene (the
DNA binding site for the transcription factor hypoxia
inducible factor-1, HIF-1) (Wenger and Gassmann,
1997), Nakayama et al. (1998) suggested that an alter-
native molecular mechanism was possibly involved in
their observed oxygen regulated AM expression. Since
the 5 promoter region of the AM gene contains two
AP-1 sites, they proposed that hypoxia upregulation of
c-fos and c-jun drives the formation of the heterodimer
AP-1, which in turn functions as the primary transcrip-
tion factor controlling AM expression at low oxygen
tension (Misha et al., 1998). In contrast to this think-
ing, our group and others have shown that hypoxia-
induced AM expression is governed by the interaction
of HIF-1 with a variety of interactive sites along the
AM promoter (Cormier-Regard et al., 1998; Garayoa et
al., 2000).
One of the classic molecular mechanisms modulating
gene expression as a result of diminished oxygen ten-
sion (i.e., 2% O2) is dependent on genomic interaction
with the HIF-1 transcription factor (Wenger and Gas-
smann, 1997). HIF-1 is composed of two protein com-
ponent subunits, HIF-1 and HIF-1 (Wenger and
Gassmann, 1997). The transcription/translation prod-
ucts of both heterodimer partners are constitutively
expressed; however, the HIF-1 protein contains an
oxygen-dependent degradative domain that is rapidly
cleaved by the ubiquitin-proteasome pathway under
normoxic conditions, thus enabling the modulation of
HIF-1 activity in an oxygen-dependent manner (Huang
et al., 1998). Recently, it has been shown that the
protein product of von Hippel-Lindau (VHL) tumor
suppressor gene binds to HIF-1 and mediates its ubiq-
uitination/proteosomal degradation under normoxic
conditions (Tanimoto et al., 2000). Interestingly, muta-
tions in VHL can lead to cell transformation and tumor
development, in part caused by the elevation of HIF-
1, which in turn drives hypoxia-regulated gene ex-
pression products such as the angiogenesis factor
VEGF to be actively generated (Kondo and Kaelin,
2001). Many human tumors have been shown to have
elevated HIF-1 via a variety of molecular mechanisms
(hypoxia, mutational VHL, etc.) and thus have a pre-
disposition for neovascularization events to occur
which augments cancer progression (Zhong et al.,
1999). AM is one of the modulatory genes upregulated
in normal and cancer cells as a result of HIF-1 eleva-
tion, which in turn conveys a selective growth bias to
their host cells (Cormier-Regard et al., 1998; Garayoa
et al., 2000).
Investigative studies generated in William Clay-
comb’s group from Louisiana State University Medical
Center were the first published reports to establish the
existence of a HIF-1 regulatory mechanism controlling
AM expression in cardiomyocytes (Cormier-Regard et
al., 1998; Nguyen and Claycomb, 1999). Using differ-
ential display and RT-PCR, they showed that AM
mRNA expression in the adult ventricular cardiac mus-
cle was 4-fold higher than that observed for its coun-
terpart tissue in E17 embryonic rat. Exposure of adult
rat ventricular cardiac myocytes to hypoxic conditions
(1% O2) caused a time-dependent increase in AM mes-
sage expression which at 12 hours was 2.2-fold greater
than the corresponding normoxic control time point.
These investigators identified two tentative base mo-
tifs in the 5 promoter region of the mouse AM gene
(1095 bp and 770 bp from the transcriptional start
site) which were similar in sequence to previously re-
ported HREs for other HIF-1 regulated genes (VEGF,
erythropoietin, and lactate dehydrogenase). When the
5 promoter of mouse AM was linked to a luciferase
reporter, upregulation of enzyme expression was de-
tected under hypoxic conditions. Site-directed mu-
tagenesis demonstrated that the 1095 bp motif was
the main HRE component responsible for hypoxia-
induced luciferase activity. To prove that this potential
HRE site would actually bind HIF-1, an 18-bp double-
stranded oligonucleotide [32P] labeled probe was pro-
duced containing the 1095 bp motif. When this probe
was mixed with the nuclear extract from hypoxia-
treated myocytes, a positive gel shift response was
observed, indicating HIF-1 complex formation. The nu-
clear extract from normoxic myocytes or mutated probe
failed to demonstrate complex formation. Hence, this
group’s combined studies generated clear evidence of
an AM/HIF-1 regulatory loop existing in myocytes.
Our laboratory has also shown that a similar AM/
HIF-1 regulatory component is in place for a variety of
human epithelial cancer cell lines and that this rela-
tionship may convey a selective growth advantage to
the tumor cell during carcinogenesis (Garayoa et al.,
2000). We have demonstrated, using Northern analy-
sis, that exposure to hypoxia or hypoxia mimetics (des-
ferrioxamine mesylate [DFX] and cobalt chloride
[CoCl2]) can dramatically increase AM message (2–20-
fold)/protein (3-fold) expression in cancer cells (Fig. 1).
Irrespective of their tissue of origin (carcinomas of the
lung, breast, colon, prostate, and ovary), all of our
hypoxia-treated cancer cell lines responded with a
marked increase in AM mRNA expression. Hypoxia
time-course studies revealed that enhanced AM tran-
script production was detected as early as 4 hours after
exposure to reduced oxygen tension, maximized at
12 hours and maintained a maximal response following
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48 hours of treatment (Fig. 2). The interdependency of
an intact HIF-1 molecule on hypoxia-induced AM ex-
pression was demonstrated using immortalized embry-
onic mouse cells from HIF-1 or HIF-1 knockout mice.
Using HIF-1/HIF-1 null mice fibroblast/stem cells,
we have shown the absolute requirement for a func-
tional HIF-1 transcription factor to drive hypoxia- or
hypoxia mimetic-induced upregulation of AM mRNA
(Garayoa et al., 2000). We have also determined that
RNA stabilization is in part responsible for the en-
hanced AM mRNA expression observed following hyp-
oxia treatment of human cancer cells (Garayoa et al.,
2000). In the human AM gene (GenBank accession No.
D43639), we have identified 20 potential HRE sites
distributed through the molecular structure, including
motifs within the 5 promoter, the 3-flanking region,
introns/exons and readable on both sense and anti-
sense strands. Reporter studies in MCF-7 (breast can-
cer cell line) with select HREs were capable of enhanc-
ing luciferase activity following exposure to DFX and
transient coexpression of HIF-1 resulted in an aug-
mented transactivation of the reporter gene after DFX
treatment, thus further supporting the role of HIF-1 in
this hypoxia-induced event. As a final inference to our
collective studies in this area, we postulate that HIF-
1-regulated AM expression may be a critical pathway
in human carcinogenesis, given that most solid tumors
are hypoxic by nature and that AM can function as an
important survival factor (stimulating tumor growth,
driving regional neovascularization, suppressing pro-
grammed cell death, and evading immune surveil-
lance).
Over the last 3 years several laboratories have now
confirmed the ability of hypoxic exposure to upregulate
AM expression in a diverse number of normal human,
rodent, and canine cells. Short-term cultures of human
coronary artery endothelial cells, umbilical vein endo-
thelial cells (HUVEC), and retinal pigment epithelial
cells have been shown to respond in this manner (Na-
kayama et al., 1999; Ogita et al., 2001; Udono et al.,
2001). The studies performed by Ogita et al. (2001) on
HUVEC not only confirmed that reduced oxygen ten-
sion increased the half-life of AM message but that it
also enhanced gene transcription rate, as determined
by nuclear run-off analysis. Hypoxia-induced augmen-
tation of AM expression has also been observed in
Fig. 1. Upregulation of AM mRNA in several human tumor cell
lines under hypoxic or hypoxia mimetic treatment. Northern blot
analysis for AM on cells exposed either to hypoxia mimetics (100 	M
CoCl2 or 260 	M DFX) for 6 hours, or to a hypoxic atmosphere (1% O2,
5% CO2, and 94% N2) for 12 hours, as compared with untreated cells.
Cell lines shown here were selected from a total of 17 cell lines tested
and also chosen as representatives of the main human tumor types:
carcinoma (CA) of the lung (N417 [small cell CA], H1264 [adeno CA],
H157 [squamous CA]), breast CA (H2380), colon CA (SNUC-1), ovar-
ian CA (SK-OV-3), prostate CA (DU145), and chondrosarcoma (HTB-
94). Fifteen micrograms of total RNA were loaded per lane and
ethidium bromide staining of 28 S rRNA was used to check for equal
loading and RNA integrity. (Reprinted with permission, Molecular
Endocrinology, Garayoa et al., 2000.)
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canine kidney cells, rat vascular smooth muscle cells,
and rat mesangial cells (Nagata et al., 1999). Recent in
vivo experiments on hypoxic rats have revealed that
transcription/translation for AM and AM-R dramati-
cally increases in lung tissue as compared to levels
observed in the normoxic animal (Hofbauer et al., 2000;
Qing et al., 2001). These pulmonary responses can be
simulated by inhalation of carbon monoxide (CO) or by
subcutaneous challenge with cobalt chloride (Hofbauer
et al., 2000). Given the fact that cigarette smokers are
at high risk of developing lung cancer, it is interesting
to note that smoking can cause pulmonary hypoxia and
elevate CO levels in the upper/distal airway. Do such
anatomical events ultimately lead to elevated lung AM/
AM-R levels in humans and, if so, is this one of the
underlying causes by which individuals become predis-
posed to malignant transformation? Hopefully, over
the next several years these questions can be properly
addressed and the resulting answers increase our un-
derstanding of AM’s role in cancer.
AM AS A SURVIVAL FACTOR IN
HUMAN CARCINOGENESIS
In the Introduction, we assigned four functional at-
tributes to AM which could selectively enhance the
growth of tumor cells during the carcinogenesis pro-
cess. These proliferative characteristics include the
ability of AM to function as a direct mitogen, its capac-
ity to act as an inhibitor of programmed cell death, its
potential to stimulate neovascularization, and its abil-
ity to suppress the immune response (Kato et al., 1997;
Zhao et al., 1998; Kamoi et al., 1995; Kubo et al., 1998a;
Miller et al., 1996).
We have previously reviewed our work with human
tumor cell lines, where we showed that a variety of
anatomically distinct cancer cell lines possess an AM/
AM-R autocrine/paracrine loop capable of augmenting
tumor cell growth in vitro. This proliferative mecha-
nism could be effectively blocked with a neutralizing
monoclonal antibody, MoAb-G6, in a dose-dependent
fashion (Miller et al., 1996). We have recently applied
this same strategy to nude mouse xenografts and have
found that MoAb-G6 can significantly suppress tumor
growth (breast CA and bronchioloalveolar CA) in this
animal model when compared to results for an isotypic
control treatment group (unpublished observation).
This is actually the first preclinical information that
implies the usefulness of anti-AM reagents as being
appropriate for therapeutic intervention in cancer.
The initial work by Kato et al. (1997) which identi-
fied AM as an autocrine/paracrine apoptosis survival
factor for rat endothelial cells was a landmark study
which opened up the possibility that a similar relation-
ship may exist in tumor cells (Cuttitta et al., 1999;
Garayoa et al., 2000). These investigators have also
shown that AM inhibition of programmed cell death in
rat endothelial cells was mediated through a cAMP-
independent pathway (Kato et al., 1997). Follow-up
experiments by Hirata’s group (Shichiri et al., 1999)
showed that AM suppression of apoptosis via serum
deprivation in rat aortic endothelial cells was mediated
through the upregulation of Max basic-helix-loop-helix-
leucine zipper protein. Normally, Max forms a het-
erodimer with c-Myc and the resulting complex func-
tions as a transcription factor binding to the E-box
recognition site (CACGTG), thus stimulating cell pro-
liferation or apoptosis (Blackwell et al., 1993). It has
been proposed by Hirata’s group that when Max is
overexpressed in endothelial cells treated with AM,
Max-Max homodimers are formed which lack tran-
scriptional activation domain and repress Myc-Max
formation/function, thus resulting in a blockage of pro-
grammed cell death. The ability of Max–Max complex
to act as a dominant negative inhibitor of Myc–Max-
induced transcription was shown by Shichiri et al.
(1999) using a preproendothelin-1 promoter containing
Fig. 2. Time course analysis of AM expression. Northern blot
analysis of MCF-7 (breast CA) cells cultured under 100 	M CoCl2 (A),
260 	M DFX (B), or 1% O2 (C) for the indicated times. Fifteen
micrograms of total RNA were loaded per lane and hybridized subse-
quently with human AM and human HIF-1 cDNA probes. Equal
loading was monitored by ethidium bromide staining of 28 S rRNA for
each blot. (Reprinted with permission, Molecular Endocrinology, Ga-
rayoa et al., 2000.)
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the Myc-Max bind consensus sequence. They observed
a diminution in promoter activity when cotransfecting
with Max- and Mad-expressing plasmids. Promoter ac-
tivation was also blocked by the addition of AM or
CGRP. In addition, Max antisense oligonucleotides
were shown to abrogate AM-mediated inhibition of en-
dothelial cell apoptosis.
Finally, AM has been proven to be an angiogenic
factor capable of stimulating neovascularization in the
chick chorioallantoic membrane (CAM) assay at nano-
gram concentrations with similar potency to b-FGF
(Zhao et al., 1998). These investigators have also
shown that AM can induce the cell growth of freshly
isolated HUVECs in culture. As previously mentioned,
Rees’s laboratory has shown that AM expression in
uterine leiomyoma correlates with vascular density of
the tumor (Hague et al., 2000). Recently, the same
group used a steroid-sensitive endometrial carcinoma
cell line (Ishikawa) to demonstrate that hypoxia in-
duced AM production upregulated Bcl-2 expression,
which in turn protected the cancer cell from apoptosis
caused by low oxygen insult (Oehler et al., 2001). Ish-
ikawa cells were shown to have CRLR/RAMP2 recep-
tors and the exogenous addition of AM caused a dose-
dependent inhibition of hypoxia-induced apoptosis in
this carcinoma cell line. In addition, Ishikawa cells
stably transfected with AM overexpressed Bcl-2 and
were resistant to hypoxia-mediated cell death. These
investigators suggest that the combined biological
characteristics of AM, stimulator of angiogenesis and
suppressor of programmed cell death, serve to promote
the carcinogenesis pathway.
CONCLUSION
We have tried to give a collective overview of what is
known about the role of AM in human carcinogenesis.
Clearly, in the past 8 years since its initial discovery,
AM has been shown to have several intriguing biolog-
ical characteristics and mediate a variety of cellular
responses which would promote tumor cell growth (Fig.
3). Cancer cells expressing AM/AM-R have the poten-
tial for an autocrine/paracrine mechanism of growth
promotion, as summarized in Table 1. Inflammation
and hypoxia appear to be the most consistent inducers
of AM/AM-R expression associated with malignant dis-
ease. AM has been demonstrated to be a direct mito-
gen, functioning as a stimulator of neovascularization
and a suppressor of programmed cell death. Such bio-
logical attributes are thought to play a critical role in
tumor development and hence represent rational tar-
gets to devise intervention strategies for use in the
clinical arena.
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